These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 8175100)

  • 1. [Moclobemide in treatment of somatoform depression. A case report].
    Rütten J
    Fortschr Med; 1994 Mar; 112(7):95-6. PubMed ID: 8175100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression in medical illness. Workshop report.
    Paykel E
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):205-7. PubMed ID: 8468445
    [No Abstract]   [Full Text] [Related]  

  • 3. RIMA: a safe concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():7-11. PubMed ID: 1394030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moclobemide for depression.
    Drug Ther Bull; 1994 Jan; 32(1):6-8. PubMed ID: 7635005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor. A case study.
    Ebert D; Demling J
    Pharmacopsychiatry; 1991 Nov; 24(6):229-31. PubMed ID: 1687486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depression: advances in drug treatment.
    Hopkins S
    Nurs Stand; 1993 Nov 24-30; 8(10):36. PubMed ID: 8297750
    [No Abstract]   [Full Text] [Related]  

  • 8. New perspectives on the treatment of depression.
    Lapierre YD
    Can J Psychiatry; 1992 Sep; 37 Suppl 1():3. PubMed ID: 1394028
    [No Abstract]   [Full Text] [Related]  

  • 9. The Australian multicentre moclobemide trial.
    Stanton J
    Aust N Z J Psychiatry; 1993 Mar; 27(1):158. PubMed ID: 8481158
    [No Abstract]   [Full Text] [Related]  

  • 10. Somatization, co-morbidity, and the quality of life: measuring the effect of depression upon chronic medical illness.
    Sullivan M; Katon WJ; Russo J; Dobie R; Sakai C
    Psychiatr Med; 1992; 10(3):61-76. PubMed ID: 1410546
    [No Abstract]   [Full Text] [Related]  

  • 11. Thyroid functioning during treatment for depression.
    Kusalic M; Engelsmann F; Bradwejn J
    J Psychiatry Neurosci; 1993 Nov; 18(5):260-3. PubMed ID: 8297924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of augmentation with moclobemide on symptoms of schizophrenia.
    Silver H; Aharon N; Hausfater N; Jahjah N
    Int Clin Psychopharmacol; 1999 May; 14(3):193-5. PubMed ID: 10435775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary open-label study of moclobemide treatment of pain disorder.
    Pirildar S; Sezgin U; Elbi H; Uyar M; Zileli B
    Psychopharmacol Bull; 2003; 37(3):127-34. PubMed ID: 14608245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moclobemide in patients with dementia and depression.
    Amrein R; Martin JR; Cameron AM
    Adv Neurol; 1999; 80():509-19. PubMed ID: 10410765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moclobemide.
    Ewart S
    Aust Nurses J; 1992; 22(5):32-3. PubMed ID: 1492825
    [No Abstract]   [Full Text] [Related]  

  • 16. [Special aspects of antidepressive therapy].
    Nervenarzt; 1994 Mar; 65(3 Suppl [speziell]):1-8. PubMed ID: 9218059
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.
    Ramasubbu R
    J Psychiatry Neurosci; 1999 Jan; 24(1):45-50. PubMed ID: 9987207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pseudohallucinations associated with moclobemide: a case report.
    Degner D; Kropp S; Porzig J; Grohmann R; Rüther E
    Pharmacopsychiatry; 2005 Jul; 38(4):179-81. PubMed ID: 16025422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Social phobia: long-term treatment outcome and prediction of response--a moclobemide study.
    Versiani M; Amrein R; Montgomery SA
    Int Clin Psychopharmacol; 1997 Sep; 12(5):239-54. PubMed ID: 9466158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.
    Sternic N; Kacar A; Filipovic S; Svetel M; Kostic VS
    Clin Neuropharmacol; 1998; 21(2):93-6. PubMed ID: 9579294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.